Objective: The function of the exocrine pancreas is decreased in patients with type 1 diabetes but it is not known when this defect develops. The current study set out to determine whether the reduced exocrine function becomes manifest after the initiation of islet autoimmunity.
| INTRODUCTION
Previous studies have suggested that the function of the exocrine pancreas is impaired in 43% to 80% of patients with type 1 diabetes. [1] [2] [3] However, the underlying mechanisms are poorly understood, and several hypotheses have been put forward, including an autoimmune process against exocrine pancreas, a decreased trophic effect of insulin on the exocrine pancreas, microangiopathy, atherosclerosis and diabetic neuropathy. 4 It has also been hypothesized that pancreatic insufficiency could be related to a specific subtype of diabetes in which the whole organ is affected (type 3c diabetes). 5, 6 Recent studies have provided new insights into the disease process affecting pancreas tissue in type 1 diabetes. One of the key findings is that the size of the whole organ is clearly reduced, and this decrease can be seen already within months after the diagnosis of type 1 diabetes. 7 Another study carried out in the nPOD (Network for Pancreatic Organ Donors with Diabetes) collection showed that the weight of the pancreas was reduced not only in patients with type 1 diabetes but also in prediabetic individuals who tested positive for islet autoantibodies. 8 In addition, studies in the nPOD collection have shown that exocrine tissue is affected by inflammation.
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The present study evaluates whether elastase concentrations in stools, as one of the most widely used biomarker of the function of exocrine pancreas, is reduced in children with newly diagnosed type 1 diabetes, and whether a possible reduction can be observed already at the early preclinical stage of the disease, close to the time when the first autoantibodies appear.
| METHODS

| Study design
The study cohort included 81 case children who had either newly Table S1 , Supporting Information.
All study subjects had written parental consent to take part in the study. The Ethics Committees of Oulu, Tampere and Turku University Hospitals in Finland have approved the DIPP study protocol.
| Measurement of stool elastase concentration
A stool sample was available for elastase analyses from the time of autoantibody seroconversion from 53 case children (samples taken from 11 weeks before to 14 weeks after the first autoantibody positive serum) and from the time of diabetes diagnosis from 28 case children (taken from 9 weeks before to 1 week after diagnosis).
Three children had samples from both time-points. In addition, long series of stool samples were available from 3 additional children to evaluate changes in elastase levels over time (mean 11 samples per child). All stool samples were stored at -20 C to −70 C until analyzed.
Pancreatic elastase-1 (PE-1) was measured using a commercial enzyme-linked immunosorbent assay according to the manufacturer's protocol (ScheBo Biotech, Giessen, Germany). Stool specimens were prepared by the E1 Quick-Prep device (ScheBo Biotech, Giessen, Germany) and the sample was diluted 56-fold before analyses. The results were expressed in μg/g of stool, and values less than 200 μg/g were considered as markers of exocrine pancreatic insufficiency and values less than 100 μg/g as markers of severe insufficiency in both case and control children according to the manufacturer's instructions. 
| Statistical methods
| RESULTS
Elastase levels did not differ between the 53 case and 53 control children at the time of islet autoantibody seroconversion (mean 1013 versus 1203 μg/g; median 738 versus 877 μg/g, P = .149; Figure 1A ).
Low elastase levels (< 200 μg/g of stool) were seen in 5 (9.4%) of the case children and in 1 (1.9%) of their controls (P = .093).
Elastase levels were significantly lower in stool samples collected from the 28 newly diagnosed type 1 diabetic patients compared to their matched controls (mean 355 versus 828 μg/g; median 230 versus 483 μg/g, P = .0006; Figure 1B ). Low levels (<200 μg/g of stool)
were seen in 11 (39.3%) of the case children and in 2 (7.1%) controls (P = .004).
Among the 41 children who progressed to clinical diabetes low elastase levels at autoantibody seroconversion did not explain the speed of progression even though a tendency for faster progression was seen (P = .1033 in linear regression analysis). Five of them (12%) had initially low elastase levels (< 200 μg/g), and they progressed to diabetes in 61.3 months (mean) compared to 48.1 months in children with higher elastase levels.
A large set of follow-up stool samples was available from 3 children ranging from the age of 3 to 6 months to the diagnosis of diabetes. A decreasing trend was seen in elastase levels towards diabetes in all of them. In 1 patient, elastase levels decreased gradually showing considerable fluctuation (Figure 2A ). In another patient elastase levels rapidly declined soon after autoantibody seroconversion and stayed at low levels until diabetes was diagnosed ( Figure 2B ). In the third patient, the elastase concentration decreased sharply at 3.5 months of age already before islet autoantibody seroconversion and remained at low levels until clinical diabetes was diagnosed ( Figure 2C ). results suggest that repeated measurements of stool elastase levels offer a feasible way to identify a significant part of children whose pancreas function decreases prior or after the diagnosis of type 1 diabetes. As a non-invasive method this could be used as a primary screening tool in young children, and be supplemented by confirmatory assays such as measurement of serum lipase levels. 13 The measurement of elastase concentrations in stools by enzyme-linked immunosorbent assay (EIA) has long been used to evaluate exocrine pancreatic function in clinical practice. 14, 15 Elastase is synthesized by the acinar cells along with the other digestive enzymes, and it is not significantly degraded during intestinal transit. Its concentration in human feces is about 5-to 6-fold higher than in pancreatic-duodenal juice. It is also stable in stool samples for up to 1 week at room temperature 13 and is not degraded during a long-term storage at −20 C. 16, 17 The good stability during storage at freezer was also suggested by our observation that elastase concentrations did not differ by an inflammatory process and fibrosis 18 and that this process can start already before type 1 diabetes is diagnosed. Recent studies have also shown that the size of the whole organ is decreased both in patients and in autoantibody-positive prediabetic individuals. 7, 8 Altogether, these studies suggest that type 1 diabetes is not only a disease of the beta-cells, but a disease which may affect the whole pancreas. It is unclear whether the FIGURE 2 Pancreatic elastase-1 concentration in serial stool samples collected from 3 children who were followed from birth and turned positive for islet autoantibodies and progressed to clinical type 1 diabetes (panels A, B and C). The time of the collection of the first islet autoantibody positive serum and the time of the diagnosis of type 1 diabetes are marked by white and black arrows, respectively. , pancreatic elastase-1;
| DISCUSSION
, insulin autoantibodies (IAA); , islet cell autoantibodies (ICA); , glutamic acid decarboxylase autoantibodies (GADA);
, insulinoma-associated protein 2 antibodies (IA-2A). Cutoffs of autoantibody units are described in Table S1 , Supporting Information exocrine dysfunction is caused by the same mechanisms as the beta-cell damaging process or if it is secondary to endocrine damage and/or inflammatory changes.
The observed decrease in elastase levels in 40% of the patients with newly diagnosed type 1 diabetes is in line with previous publications. 13 Thus, even if the average elastase levels are lower in patients than in controls only few of them may have clinically significant pancreas insufficiency. In any case, the present study clearly shows that elastase is associated with advanced beta-cell damage in young children. As the study included only young children and the majority of the samples were collected before the age of 3 years, it was not possible to study the occurrence of pancreatic insufficiency in older children.
In conclusion, the results suggest that a defect in exocrine function develops in about 40% of the patients during the progression of islet autoimmunity to clinical type 1 diabetes. This may open possibilities to use stool elastase levels as a biomarker for the progression of the beta-cell damaging process. As the method is simple, non-invasive and technically easy to perform, further studies are indicated to find out whether it could offer a new tool to predict the development of type 1 diabetes in autoantibody-positive individuals.
